Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design
On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though investors are watching for more detail.
Recursion Pharmaceuticals (RXRX) experienced a 4% increase on November 18 following its FDA alignment on the Phase 3 design for REC-4881, a clinical-stage drug discovery aimed at familial adenomatous polyposis. The company's stock rose to $2.83, up from its previous close of $2.72. Trading volume reached 39.4 million shares, a 65% increase compared to its three-month average of 23.8 million shares.
Recursion, which went public in 2021, has seen its shares plummet by 91% since its initial public offering. The company believes there are over 50,000 patients with familial adenomatous polyposis in the U.S. and E.U., presenting a substantial $15 billion market opportunity for REC-4881. The FDA accepted the primary endpoint of event-free survival for 10 mm or larger polyp excision, potentially eliminating the need for a longer, more costly trial.
However, the success of the Phase III trial, set to commence in the second half of 2027, remains vital, as it holds the potential to validate Recursion's AI platform and demonstrate a proof of concept.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.